<DOC>
	<DOCNO>NCT01630083</DOCNO>
	<brief_summary>The purpose trial ass therapeutic effect safety profile IMAB362 combine EOX ( epirubicin , oxaliplatin , capecitabine ) first-line treatment patient advance adenocarcinoma stomach , esophagus gastroesophageal junction compare EOX alone . Furthermore , sufficient bind IMAB362 target cell necessary antitumoral activity . Thus , two dose level ensure serum level vitro predict clinical efficacy threshold investigate .</brief_summary>
	<brief_title>Efficacy Safety IMAB362 Combination With EOX Regimen CLDN18.2-positive Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically confirm adenocarcinoma stomach , esophagus gastroesophageal junction Inoperable locally advance disease resection R2 outcome recurrent metastatic disease . CLDN18.2 expression confirm immunohistochemistry paraffin embed tumor tissue sample . Measurable and/or nonmeasurable disease define accord RECISTv1.1 Age ≥ 18 year Written Informed Consent Form ECOG performance status ( PS ) 01 Life expectancy &gt; 3 month HER2/neu negative patient patient HER2/neu positive status eligible trastuzumab therapy discretion investigator . Adequate cardiac , hepatic , renal , hematologic function . Prior severe allergic reaction intolerance monoclonal antibody , chemotherapeutics use study excipient respective formulation . Previous chemotherapy advance disease . Previous perioperative chemotherapy curative intention within 6 month start study treatment . If interval long 6 month ( count stop date perioperative chemotherapy ) , patient allow . Known HIV infection know symptomatic hepatitis ( A , B , C ) . Symptomatic cerebral metastasis . Pregnancy breastfeed . Previous treatment maximum cumulative dos epirubicin &gt; 500 mg/m² and/or anthracyclines anthracenediones . Known dihydropyrimidine dehydrogenase ( DPD ) deficiency .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>